Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more
Welcome back to Endpoints Weekly! Merck and Moderna dominated the headlines this week with topline results for their personalized cancer vaccine. Check out our team’s detailed analysis on the results, the unknowns and Moderna’s massive ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.